← Back to Search

Anticoagulant

Warfarin for Deep Vein Thrombosis (CANVAS Trial)

N/A
Waitlist Available
Research Sponsored by Alliance Foundation Trials, LLC.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of advanced solid tumor cancer, lymphoma, or myeloma (no time restrictions or limitations) -OR- diagnosis of early stage solid tumor cancer, lymphoma, or myeloma <= 12 months prior to study enrollment
Diagnosis of VTE <= 30 days prior to study enrollment for which potential benefits of anticoagulation therapy to prevent recurrence of VTE are felt by the treating physician to exceed the potential harms
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

CANVAS Trial Summary

This trial is testing if a new type of blood thinner is more effective than the current standard of care in preventing cancer patients from having another blood clot.

Eligible Conditions
  • Deep Vein Thrombosis (DVT)
  • Deep Vein Thrombosis
  • Cancer
  • Pulmonary Embolism
  • Blood Clot

CANVAS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

CANVAS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6-months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cumulative Non-Fatal VTE Recurrence at 6 Months (%)
Secondary outcome measures
Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
Cumulative Rates of Major Bleeding
+4 more

CANVAS Trial Design

4Treatment groups
Active Control
Group I: Randomized Arm 2 (LMWH)Active Control4 Interventions
Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
Group II: Randomized Arm 1 (DOACs)Active Control4 Interventions
Randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC). There are four FDA-approved DOAC drugs that may be used for this study: Rivaroxaban, Apixaban, Edoxaban, or Dabigatran. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
Group III: Preference Cohort 1 (DOACs)Active Control4 Interventions
If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized). Preference cohort: Non-randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC).
Group IV: Preference Cohort 2 (LMWH)Active Control4 Interventions
If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized). Preference cohort: Non-randomized Arm 2 will get anticoagulation therapy with Low Molecular Weight Heparin (LMWH) with or without a transition to warfarin.

Find a Location

Who is running the clinical trial?

Alliance Foundation Trials, LLC.Lead Sponsor
23 Previous Clinical Trials
24,221 Total Patients Enrolled
Patient-Centered Outcomes Research InstituteOTHER
548 Previous Clinical Trials
29,995,776 Total Patients Enrolled
2 Trials studying Deep Vein Thrombosis
435,652 Patients Enrolled for Deep Vein Thrombosis
Jean Connors, MDStudy ChairAlliance Foundation Trials, LLC.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being accepted into the research project?

"Unfortunately, the original trial is no longer accepting participants. Initially posted on December 1st 2016 and last updated on May 6th 2022, this study has been closed for enrollment. However, if you're searching for alternate trials there are currently 746 studies recruiting patients with malignancies and 134 clinical trials seeking enrollees who take Warfarin."

Answered by AI

What diseases can Warfarin effectively ameliorate?

"Warfarin can be prescribed for surgical intervention, systemic embolism, hip architecture issues, and unstable angina pectoris."

Answered by AI

Are there numerous sites in North America that are administering this trial?

"100 different trial sites are hosting this clinical trial, including the Southeastern Medical Oncology Center in Clinton, Hackensack University Medical Center in Hackensack, and Kalispell Regional Medical Center. Additionally, there are numerous other locations participating nationwide."

Answered by AI

What investigatory work has been done to explore the properties of Warfarin?

"At the moment, 134 Warfarin studies are taking place with 49 Phase 3 trials. Although Montreal, Quebec is a hotspot for this type of research, there are more than two thousand other locations where investigations into this medication occur."

Answered by AI

Has enrollment begun for this experiment?

"Clinicaltrials.gov reveals that this trial, initially posted in December 2016 and last updated on May 6th 2022, is not actively looking for patient recruitment at the moment; however, there are 880 other studies which require participants to join their trials presently."

Answered by AI
~98 spots leftby Mar 2025